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Abstract
Signal transducer and activator of transcription (Stat) 3 is an oncogene constitutively activated in many cancer systems
where it contributes to carcinogenesis. To develop chemical probes that selectively target Stat3, we virtually screened
920,000 small drug-like compounds by docking each into the peptide-binding pocket of the Stat3 SH2 domain, which
consists of three sites—the pY-residue binding site, the +3 residue-binding site and a hydrophobic binding site, which
served as a selectivity filter. Three compounds satisfied criteria of interaction analysis, competitively inhibited recombinant
Stat3 binding to its immobilized pY-peptide ligand and inhibited IL-6-mediated tyrosine phosphorylation of Stat3. These
compounds were used in a similarity screen of 2.47 million compounds, which identified 3 more compounds with similar
activities. Examination of the 6 active compounds for the ability to inhibit IFN-c-mediated Stat1 phosphorylation revealed
that 5 of 6 were selective for Stat3. Molecular modeling of the SH2 domains of Stat3 and Stat1 bound to compound
revealed that compound interaction with the hydrophobic binding site was the basis for selectivity. All 5 selective
compounds inhibited nuclear-to-cytoplasmic translocation of Stat3, while 3 of 5 compounds induced apoptosis
preferentially of breast cancer cell lines with constitutive Stat3 activation. Thus, virtual ligand screening of compound
libraries that targeted the Stat3 pY-peptide binding pocket identified for the first time 3 lead compounds that competitively
inhibited Stat3 binding to its pY-peptide ligand; these compounds were selective for Stat3 vs. Stat1 and induced apoptosis
preferentially of breast cancer cells lines with constitutively activated Stat3.
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Introduction
Signal transducer and activator of transcription 3 (Stat3) is an
oncogene [1] and one of seven members of the Stat protein family,
which are signaling intermediates that mediate the actions of many
cytokines and growth factors. Stat3 is constitutively active in many
different cancers including prostate, breast, lung, head and neck,
colon, liver, and pancreas as well as in multiple myeloma and large
granular lymphocytic leukemia [2–8]. Furthermore, human tumor
xenograft studies in mice have repeatedly demonstrated that
inhibiting Stat3 results in decreased tumor growth and improved
animal survival [4] by inducing apoptosis in tumor cells, inhibiting
angiogenesis [9] and enhancing anti-tumor immune-mediated
cytotoxicity [2,10]. Thus, Stat3 has been identified as a potentially
high-yield targetfor drug developmenttotreatmany cancers[11–13].
IncontrasttoStat3,Stat1 isanti-oncogenic;itisapotentinhibitor
of tumor growth and promoter of apoptosis [1]. Also, because
tumors from carcinogen-treated wild-type animals grow more
rapidly when transplanted into theStat1-deficientanimals than they
do in a wild-type host, Stat1 contributes to tumor immunity [14].
Consequently, a highly desirable goal in the development of drugs
that target Stat3 is selectivity for Stat3 vs. Stat1.
We and others have developed drugs that selectively target Stat3
vs. Stat1[15–20]. However, determination of their selectivity was
established empirically after their identification as Stat3 inhibitors
and was not built into the screening process. In this paper, we
describe a small-molecule, virtual ligand screening approach that
targets the pY-peptide binding pocket of the Stat3 SH2 domain at
three sites including a hydrophobic pocket, which served as a
selectivity filter. This approach identified for the first time 3 novel
lead compounds that competitively inhibit Stat3 binding to its pY-
peptide ligand, that are selective for Stat3 vs. Stat1 and that also
induce apoptosis preferentially of breast cancer cells lines with
constitutively activated Stat3. In addition to yielding compounds
that selectively target Stat3 by design, the approach described has
potential for identifying selective, chemical probes of other
members of the Stat protein family.
Methods
Virtual ligand screening
We isolated the three-dimensional structure of the Stat3 SH2
domain from the core fragment structure of phosphorylated Stat3
homodimers bound to DNA [21] deposited in the RCSB Protein
Data Bank (PDB) databank (PDB code 1BG1) and converted it to
be an Internal Coordinate Mechanics (ICM)-compatible system by
adding hydrogen atoms, modifying unusual amino acids, making
charge adjustments and performing additional cleanup steps. In
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from the PDB databank (PDB code 1BF5) for use in computa-
tional selectivity analysis [22]. Commercial chemical databases
(ChemBridge, Asinex, ChemDiv, Enamine, KeyOrganics and
LifeChemicals) were chosen as sources of compounds for screening
in silico. We selected the amide hydrogen of E638 within the site
that binds the +3 residue (Q, C or T) within the pY-peptide ligand
[23] as the central point of the binding pocket, which consisted of
a cube with dimensions 16.0616.9613.7 angstrom. In addition to
the +3 binding site, this cube contained the pY residue binding site
consisting mainly of R609 and K591 [23] and a hydrophobic
binding site consisting of 5 residues—W623, Q635, V637, Y640
and Y657. Alignment of the residues of Stat3 from W623 to Y657
that contain the hydrophobic binding site and the corresponding
residues of Stat1 revealed a difference in 1 of these 5 residues
(Q635 in Stat3 vs. H629 in Stat1). In addition, there was only 40%
homology in the remaining residues within this region. Also,
overlay of the Stat3 and Stat1 SH2 domain peptide backbone
structures did not reveal superimposition throughout this region,
particularly within LoopbC–bD (K626DISGSTQIQS636). Finally,
comparison of the orientation of the hydrophobic binding site
residues revealed that the side chain of V637 in Stat3 is pointed
into the hydrophobic binding pocket while the corresponding
residue V631 in Stat1 is pointed away from the pocket. These
considerations raised the possibility that the hydrophobic binding
site might serve as a selectivity filter [24]. A flexible docking
calculation [25] was performed in order to determine the global
minimum energy score and thereby predict the optimum
conformation of the compound within the pocket. A compound
was selected for purchase and biochemical testing based on
fulfilling the criteria of interaction analysis (CIA): 1) global
minimum energy score #230; 2) formation of a salt-bridge
and/or H-bond network within the pY-residue binding site; and 3)
formation of an H-bond with or blocking access to the amide
hydrogen of E638. Most, but not all, compounds also interacted
with the hydrophobic binding site.
Stat3/pY-peptide binding assay
Stat3 binding assays were performed at 25uC with a BIAcore
3000 biosensor using 20 mM Tris buffer pH 8 containing 2 mM
mercaptoethanol and 5% DMSO as the running buffer [26].
Phosphorylated and control non-phosphorylated biotinylated
EGFR derived dodecapeptides based on the sequence surrounding
Y1068 [27] were immobilized on a streptavidin coated sensor chip
(BIAcore inc., Piscataway NJ). The binding of Stat3 was
conducted in 20 mM Tris buffer pH 8 containing 2 mM ß-
mercaptoethanol at a flow rate of 10 mL/min for 1–2 minute.
Aliquots of Stat3 at 500 nM were premixed with compound to
achieve a final concentration of 1–1,000 mM and incubated at 4uC
prior to being injected onto the sensor chip. The chip was
regenerated by injecting 10 mL of 100 mM glycine at pH 1.5 after
each sample injection. A control (Stat3 with DMSO but without
compound) was run at the beginning and the end of each cycle (40
sample injections) to ensure that the integrity of the sensor chip
was maintained throughout the cycle run. The average of the two
controls was normalized to 100% and used to evaluate the effect of
each compound on Stat3 binding. Responses were normalized by
dividing the value at 2 min by the response obtained in the
absence of compounds at 2 min and multiplying by 100. IC50
values were determined by plotting % maximum response as a
function of log concentration of compound and fitting the
experimental points to a competitive binding model using a four
parameter logistic equation: R=Rhigh2(Rhigh2R low)/ (1+conc/
A1)
A2, where R=percent response at inhibitor concentration,
Rhigh=percent response with no compound, Rlow=percent
response at highest compound concentration, A2=fitting param-
eter (slope) and A1=IC50 (BIAevaluation Software version 4.1).
Immunoblot assay
The human hepatocellular carcinoma cell line (HepG2) was
grown in 6-well plates under standard conditions. Cells were
pretreated with compounds (0, 1, 3, 10, 30, 100 and 300 mM) for
1 hour then stimulated under optimal conditions with either
interleukin-6 (IL-6; 30 ng/ml for 30 min) to activate Stat3 or
interferon gamma (IFN-c; 30 ng/ml for 30 min) to activate Stat1
[28]. Cultures were then harvested and proteins extracted using
high-salt buffer, as described [23]. Briefly, extracts were mixed with
26sodiumdodecyl sulfate (SDS) sample buffer (125 mM Tris-HCL
pH 6.8; 4% SDS; 20% glycerol; 10% 2-mercaptoethanol) at a 1:1
ratio and heated for 5 minutes at 100uC. Proteins (20 mg) were
separated by 7.5% SDS-PAGE and transferred to polyvinylidene
fluoride (PVDF) membrane (Millipore, Waltham, MA) and
immunoblotted. Prestained molecular weight markers (BioRad;
Hercules, CA) were included in each gel. Membranes were probed
serially with antibody against Stat1 pY701 or Stat3 pY705 followed
by antibody against Stat1 or Stat3 (Transduction labs, Lexington,
KY) then antibody against b–actin (Abcam, Cambridge, MA).
Membranes were stripped between antibody probing using
Restore
TM Western Blot Stripping Buffer (Thermo Fisher Scientific
Inc., Waltham, MA) per the manufacturer’s instructions. Horse-
radish peroxidase-conjugated goat-anti-mouse IgG was used as the
secondary antibody (Invitrogen Carlsbad, CA) and the membranes
were developed with enhanced chemiluminescence (ECL) detection
system (Amersham Life Sciences Inc.; Arlington Heights, IL.).
Similarity screen
Three compounds identified in the initial VLS—Cpd3, Cpd30
and Cpd188—inhibited Stat3 SH2/pY-peptide binding and IL-6-
mediated Stat3 phosphorylation and were chosen as reference
molecules for similarity screening. A fingerprint similarity query for
each reference compound was submitted to Molcart/ICM (Max
Distance,0.4). Similaritybetween eachreferencemoleculeandeach
database molecule was computed and the similarity results were
ranked in decreasing order of ICM similarity score [29]. The
databases searched included ChemBridge, LifeChemicals, En-
amine, ChemDiv, Asinex, AcbBlocks, KeyOrganics and PubChem
for a total of 2.47 million compounds. All compounds identified
were docked into the binding pocket of Stat3 SH2 domain in silico.
Compounds that fulfilled CIA criteria were purchased and tested as
described for compounds identified in the primary screen.
Molecular modeling
All 3-D configurations of the Stat3 SH2 domain complexed with
compounds were determined by global energy optimization that
involves multiple steps: 1) location of organic molecules were
adjusted as a whole in 2 A ˚ amplitude by pseudo-Brownian random
translations and rotations around the molecular center of gravity, 2)
the internal variables of organic molecules were randomly changed,
3) coupled groups within the Stat3 SH2 domain side-chain torsion
angles were sampled with biased probability shaking while the
remaining variables of the protein were fixed, 4) local energy
minimizations were performed using the Empirical Conformation
Energy Program for Peptides type-3 (ECEPP3) in a vacuum [30]
with distance-dependent dielectric constant =4r, surface-based
solvent energy and entropic contributions from the protein side
chains evaluated added and 5) conformations of the complex, which
were determined by Metropolis criteria, were selected for the next
conformation-scanning circle.
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PLoS ONE | www.plosone.org 2 March 2009 | Volume 4 | Issue 3 | e4783Figure 1. Inhibition of Stat3 binding to immobilized phosphopeptide ligand by compounds. Binding of recombinant Stat3 (500 nM) to a
BiaCore sensor chip coated with a phosphododecapeptide based on the amino acid sequence surrounding Y1068 within the EGFR was measured in
real time by SPR in the absence (0 mM) or presence of increasing concentrations (0.1 to 1,000 mM) of Cpd3 (panel A), Cpd30 (panel B), Cpd188 (panel
C), Cpd3-2 (panel D), Cpd3-7 (panel E) and Cpd30-12 (panel F). Data shown are response units as a function of time in seconds and are representative
of 2 or more experiments. The equilibrium binding levels obtained in the absence or presence of compound were normalized (response obtained in
the presence of compound 4 the response obtained in the absence of compound 6100) and plotted against the log concentration (nM) of the
compound (panel G). The experimental points for each compound fit to a competitive binding curve that uses a four-parameter logistic equation (see
Methods for details). These curves were used to calculate the IC50 value for each compound (Table 2).
doi:10.1371/journal.pone.0004783.g001
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domain in a complex with each compound was predicted and
generated by superimposing, within the computational model, the
3-dimensional features of the Stat1 SH2 domain onto the 3-
dimensional configuration of the Stat3 SH2 domain in a complex
with each compound. The peptide backbone atoms of residues
K584, R602 and E632 in Stat1 and K591, R609 and E638 in
Stat3 were used in this superimposition. The final computational
model of Stat1 SH2 in a complex with each compound was
determined by local minimization using Internal Coordinate Force
Field (ICFF)-based molecular mechanics [25]. We computed the
van der Waals energy of each complex consisting of compound
bound to the SH2 domain of Stat1 or Stat3 using Lennard-Jones
potential with ECEPP/3 force field [30].
Confocal and high-throughput fluorescence microscopy
(HTFM)
Confocal and high-throughput fluorescence microscopy (HTFM)
of MEF/GFP-Stat3a cells were performed asdescribed [31]. Briefly,
for confocal fluorescence microscopy, cells were grown in 6-well
plates containing a cover slip. For HTFM, cells were seeded into 96-
well CC3 plates at a density of 5,000 cells/well using an automated
plating system. Cells were cultured under standard conditions until
85–90% confluent. Cells were pre-treated with compound for
1h o u ra t3 7 uC then stimulated with IL-6 (200 ng/ml) and IL-6sR
(250 ng/ml) for 30 minutes to provide optimal Stat3 activation and
nuclear translocation in these cells, as described [31]. Cells were
fixed with 4% formaldehyde in PEM Buffer (80 mM Potassium
PIPES, pH 6.8, 5 mM EGTA pH 7.0, 2 mM MgCl2) for
30 minutes at 4uC, quenched in 1 mg/ml of NaBH4 (Sigma) in
PEM buffer and counterstained for 1 min in 4,6-diamidino-2-
phenylindole (DAPI; Sigma; 1 mg/ml) in PEM buffer. Cover slips
were examined by confocal fluorescent microscopy. Plates were
analyzed by automated HTFM using the Cell Lab IC Image
Cytometer (IC100) platform and Cytoshop Version 2.1 analysis
software (Beckman Coulter). Nuclear translocation is quantified by
using the fraction localized in the nucleus (FLIN) measurement [32].
FLIN values were normalized by subtracting the FLIN for
unstimulated cells then dividing this difference by the maximum
difference(delta,D) inFLIN(FLIN in cells stimulated with IL-6/sIL-
6R in the absence of compound minus FLIN of unstimulated cells).
This ratio was multiplied by 100 to obtain the percentage of
maximum difference in FLIN and was plotted, where indicated, as a
function of the log compound concentration. The best-fitting curve
and IC50 value were determined using 4-Parameter Logistic Model/
Dose Response/XLfit 4.2, IDBS software.
Breast cancer cell line apoptosis assay
Human breast carcinoma cell lines MDA-MB-468, MDA-MB-
231, MBA-MD-435 and MCF7 were kindly provided by Dr. Powel
H. Brown (Breast Cancer Center, Baylor College of Medicine).
Breast cancer cell line, MDA-MB-453 was kindly provided by Dr.
Shou Jiang (Breast Cancer Center, Baylor College of Medicine). All
cell lines were grown in DMEM medium supplemented with 10%
fetal bovine serum (FBS), 25,000 units penicillin G, 25,000 mg
streptomycin, and 131.4 mg L-Glutamine and cultured in the
incubator under the condition of 95% air, 5% CO2 at 37uC [33].
Cells were seeded at 2,500 cells/cm
2 into 12-well plates. At 80%
confluency, cells were washed with PBS and supplemented with
fresh medium containing compound or the topoisomerase I-
inhibitor, camptothecin, at 0, 0.1, 0.3, 1, 3, 10, 30, 100, 300 mM.
At 24 hours, treatment was terminated by removing the medium
from each well. Cells were lysed with cell lysis buffer (600 ml for
30 minutes at 25uC). Cell lysate (200 ml) was centrifuged at 200 g
for 10 minutes and 20 ml of each supernatant was assayed for
nucleosomesusingtheCellDeathDetectionELISA(RocheApplied
Science) as described by the manufacturer. The percent maximum
nucleosomelevel wascalculated bydividing the nucleosome level by
the maximum nucleosome level achieved in the assay and
multiplying by 100. This value was plotted as a function of the
log compound concentration and the best-fitting curve and EC50
value determined using 4-Parameter Logistic Model/Dose Re-
sponse/XLfit 4.2, IDBS software.
Results
Identification by virtual ligand screening (VLS) of
compounds that blocked Stat3 binding to its
phosphopeptide ligand and inhibited IL-6-mediated
phosphorylation of Stat3
Our VLS protocol was used to evaluate a total of 920,000 drug-
like compounds. Of these, 142 compounds fulfilled CIA criteria.
These compounds were purchased and tested for their ability to
block Stat3 binding to its phosphopeptide ligand in a surface
plasmon resonance (SPR)-based binding assay and to inhibit IL-6-
mediated phosphorylation of Stat3. SPR competition experiments
showed that of the 142 compounds tested, 3 compounds—Cpd3,
Cpd30 and Cpd188—were able to directly compete with pY-
peptide for binding to Stat3 with IC50 values of 447, 30, and
20 mM, respectively (Figure 1; Tables 1 and 2). In addition, each
compound inhibited IL-6-mediated phosphorylation of Stat3 with
IC50 values of 91, 18 and 73 mM respectively (Figure 2; Table 2).
Similarity screening with Cpd3, Cpd30 and Cpd188 identified
4,302 additional compounds. VLS screening was performed with
Table 1. Summary of compound chemical names and formulas.
Compound
1 Chemical Name Formula
Cpd3 4-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-oxo-1-propen-1-yl]benzoic acid C18H14O5
Cpd30 4-{5-[(3-ethyl-4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]-2-furyl}benzoic acid C17H13NO4S2
Cpd188 4-[({3-[(carboxymethyl)thio]-4-hydroxy-1-naphthyl}amino)sulfonyl]benzoic acid C19 H15 NO 7 S2
Cpd3-2 3-({2-chloro-4-[(1,3-dioxo-1,3-dihydro-2H-inden-2-ylidene)methyl]-6-ethoxyphenoxy}methyl)benzoic acid C26 H19 Cl O6
Cpd3-7 methyl 4-({[3-(2-methoxy-2-oxoethyl)-4,8-dimethyl-2-oxo-2H-chromen-7-yl]oxy}methyl)benzoate C23 H22 O7
Cpd30-12 4-chloro-3-{5-[(1,3-diethyl-4,6-dioxo-2-thioxotetrahydro-5(2H)-pyrimidinylidene)methyl]-2-furyl}benzoic acid C20 H17 Cl N2 O5 S
1Compound name given by our lab.
doi:10.1371/journal.pone.0004783.t001
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fulfilled CIA criteria; these were purchased and tested. SPR
competition experiments showed that of these 41 compounds, 3
compounds—Cpd3-2, Cpd3-7 and Cpd30-12—were able to
directly compete with pY-peptide for binding to Stat3 with IC50
values of 256, 137 and 114 mM, respectively (Figure 1; Tables 1
and 2). In addition, each compound inhibited IL-6-mediated
phosphorylation of Stat3 with IC50 values of 144, 63 and 60 mM,
respectively (Figure 2; Table 2).
Compound-mediated inhibition of ligand-stimulated
phosphorylation of Stat3 is specific for Stat3 vs. Stat1
While Stat3 contributes to oncogenesis, in part, through
inhibition of apoptosis, Stat1 is anti-oncogenic; it mediates the
apoptotic effects of interferons and contributes to tumor immunity
[14,34]. Consequently, compounds that target Stat3 while sparing
Stat1, leaving its anti-oncogenic functions unopposed, may result
in a synergistic anti-tumor effect. To assess the selectivity of our
compounds for Stat3 vs. Stat1, HepG2 cells were incubated with
Cpd3, Cpd30, Cpd188, Cpd3-2, Cpd3-7, and Cpd30-12
(300 mM) for 1 hour at 37uC before IFN-c stimulation
(Figure 2G). Only treatment with Cpd30-12 blocked Stat1
phosphorylation while each of the other five compounds—Cpd3,
Cpd30, Cpd188, Cpd3-2 and Cpd3-7—did not. Thus, five of the
six compounds identified were selective and inhibited ligand-
stimulated phosphorylation of Stat3 but not Stat1.
Sequence analysis and molecular modeling of the
interaction of each compound with the Stat3 vs. Stat1
SH2 domain
To understand at the molecular level the basis for the selectivity
of Cpds 3, 30, 188, 3-2 and 3-7 and the absence of selectivity in the
case of Cpd 30-12, we compared the amino-acid sequences and
the available structures of the Stat3 and Stat1 SH2 domains and
also examined how each compound interacted with both.
Sequence alignment revealed identity in the residues within Stat3
and Stat1 corresponding to the binding site for the pY-residue and
the +3 residue (Figure 3G). In addition, overlay of the Stat3 and
Stat1 SH2 structures revealed that the loops that contained these
binding sites could be superimposed (Figure 3H). In contrast,
sequence alignment revealed only 40% homology in the residues
contained within the hydrophobic binding site from W623 to
Y657 in Stat3 and the corresponding region of Stat1 (Figure 3G).
Also, overlay of the Stat3 and Stat1 SH2 domain peptide
backbone structures (Figure 3H) did not reveal superimposition
throughout this region, particularly within LoopbC–bD (K626DIS-
GSTQIQS636), and the side chain of V637 in Stat3, which is
pointed into the hydrophobic binding pocket, while the corre-
sponding residue V631 in Stat1 is pointed away from the pocket.
Review of computational models of Cpd3, Cpd30, Cpd188, Cpd3-
2 and Cpd3-7 in a complex with the Stat3 SH2 domain revealed
that each has significant interactions with the Stat3 SH2 domain
binding pocket at all three binding sites, the pY-residue binding
site, the +3 residue binding site and the hydrophobic binding site
(Figure 3A, B, C, D, and E). In contrast, Cpd30-12 interacts with
the pY-residue binding site and blocks access to the +3 residue-
binding site but does not interact with or block access to the
hydrophobic binding site (Figure 3F). In addition, while van der
Waals energies of Cpd30-12 were equivalent for its interaction
with the Stat3 SH2 domain and the Stat1 SH2 domain, the 5
selective compounds were much more favorable for their
interaction with the Stat3 SH2 domain than with the Stat1 SH2
domain (Figure 3I). Thus, computer modeling indicated that
activity of a compound against Stat3 derives from its ability to
interact with the binding sites for the pY and the +3 residues
within the binding pocket, while selectivity for Stat3 vs. Stat1
derives from the ability of a compound to interact with the
hydrophobic binding site, which served as a selectivity filter. Van
der Waals energy calculations (Figure 3I) implicated residues that
form the hydrophobic binding site (W623, Q635, V637, Y640 and
Y657) as critical for this selectivity. However, as noted previously,
there is low homology between the Stat3 SH2 domain from
residues W623 to Y657 that contain the hydrophobic binding site,
and the corresponding residues in Stat1. Several of these non-
homologous residues are polar residues raising the possibility that
polar interactions of compounds within this region may also
contribute to selectivity.
Inhibition of nuclear translocation of phosphorylated
Stat3 by Cpd3, Cpd30, Cpd188, Cpd3-2 and Cpd3-7
assessed by HTFM
Following its phosphorylation on Y705, Stat3 undergoes tail-to-
tail dimerization mediated by reciprocal SH2/pY705-peptide
ligand interactions. This conformational change is followed by
nuclear accumulation. Compounds that targeted the Stat3 SH2/
Figure 2. Effect of compounds on ligand-mediated Stat3 and Stat1 phosphorylation. HepG2 cells were pretreated with DMSO alone or
DMSO containing Cpd3 (panel A), Cpd188 (panel B), Cpd30 (panel C), Cpd3-2 (panel D), Cpd3-7 (panel E) or Cpd30-12 (panel F) at the indicated
concentration for 60 min. Cells were then stimulated with IL-6 (30 ng/ml) for 30 min. Protein extracts of cells were separated by SDS-PAGE, blotted
and developed serially with antibodies to pStat3, total Stat3 and b-actin. Blots were stripped between each antibody probing. Band intensities were
quantified by densitometry. The value of each pStat3 band was divided by its corresponding total Stat3 band intensity; the results were normalized to
the DMSO-treated control value. This value was plotted as a function of the log compound concentration. The best-fitting curve was determined
using 4-Parameter Logistic Model/Dose Response/XLfit 4.2, IDBS software and was used to calculate the IC50 value (Table 1). Each panel is
representative of 3 or more experiments. In panel G, HepG2 cells were pretreated with DMSO alone or DMSO containing each of the compounds at a
concentration of 300 mM for 60 min. Cells were then stimulated with IFN-c (30 ng/ml) for 30 min. Protein extracts of cells were separated by SDS-
PAGE and immunoblotted serially with antibodies to pStat1, total Stat1 and b-actin. Blots were stripped between each immunoblotting. The results
shown are representative of 2 or more experiments.
doi:10.1371/journal.pone.0004783.g002
Table 2. Summary of activity of compounds in inhibiting
Stat3 binding to pY peptide ligand in a surface plasmon
resonance binding (SPR) assay, in inhibiting IL-6-mediated
Stat3 phosphorylation (pStat3) and in inhibiting IL-6-mediated
Stat3 nuclear translocation in a high-throughput fluorescence
microscopy (HTFM) assay.
Assay Cpd3 Cpd30 Cpd188 Cpd3-2 Cpd3-7 Cpd30-12
SPR 447
1 30 20 256 137 114
pStat3 91 18 73 144 63 60
HTFM 131 77 39 150 20 .300
1Data presented are IC50 values (mM) obtained using results summarized in
Figures 1 (SPR), Figure 2 (pStat3) and Figure 4 (HTFM).
doi:10.1371/journal.pone.0004783.t002
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SH2 domain of Stat3 or Stat1. The 2-D structures and the results of
computerdockingofeachcompoundtotheStat3SH2 domain areshown
in panels A through F. The left side of each panel shows the 2-D structure,
the middle portion of each panel shows the compound binding to an
electrostatic molecular surface model of the Stat3 SH2 domain in which
blue represents areas of positive-charge and red represents areas of
negative-charge. The right side of each panel is a closer view of this
interaction with hydrogen bonds indicated by dotted lines. Stick models
are used to depict critical residues in the general binding site (R609, K591,
S611, E612 and S613), in the specific binding site (E638) and in the
hydrophobic site (W623, Q635, V637, Y640 and Y657) with carbon,
oxygen,nitrogenandhydrogenatomsrepresentedbysilver,red,blueand
grey, respectively. Each compound is depicted using a ball-and-stick
model with carbon, oxygen, nitrogen, sulfur, chlorine and hydrogen
atoms represented by gold, red, blue, yellow and green, respectively. In
panel A, the negatively charged benzoic acid moiety of Cpd3 has
electrostatic interactions with the guanidinium cation group of R609 and
the basic ammonium group of K591. There are double H-bonds that form
between the carboxylic oxygen and the side chain terminus hydrogen of
R609 and the amide hydrogen of E612 and H-bond formation between
the benzoic acid carbonyl oxygen and the side chain hydroxyl hydrogen
of S611. The oxygen atom of 1,4-benzodioxin forms a hydrogen bond
with the amide hydrogen of E638. In addition, the double ring group of
Cpd3 has hydrophobic interactions to the hydrophobic binding site,
which consists of W623, Q635, V637, Y640, and Y657. In panel B, the
carboxylic terminus of the benzoic acid moiety of Cpd30 has electrostatic
interactions with the to guanidinium group of R609. There are two
hydrogen bonds that form between the terminal hydrogen of R609 and
carboxylic oxygen of Cpd30 and between the terminal hydrogen of S613
and carbonyl oxygen of Cpd30. In addition, the thiazolidin moiety of
Cpd30 has hydrophobicinteractions withthehydrophobicbindingsite.In
panel C, the (carboxymethyl) thio moiety of Cpd188 has electrostatic
interactions with R609 and K591. The terminal oxygen of the
(carboxymethyl) thio group of Cpd188 forms three H-bonds: 1) with the
guanidinium hydrogen of R609, 2) with the backbone amide hydrogen of
E612 and 3) with the hydroxyl-hydrogen of S611. There is an H-bond
formation between the hydroxyl-oxygen of the benzoic acid group of
Cpd188 and the amide-hydrogen of E638. In addition, the benzoic acid
group interacts with the hydrophobic binding site, particularly V637. In
panel D, the benzoic acid group of Cpd3-2 has electrostatic interactions
with R609 and K591. There are two H bonds between the carboxylic
oxygenofthebenzoicacidgroupandguanidiniumhydrogenofR609and
between the carbonyloxygenof the benzoic acid groupand the hydroxyl
hydrogen of S611. In addition, the 1,3-dihydro-2H-inden-2-ylidene group
ofCpd30hashydrophobicinteractionswiththehydrophobicbindingsite.
In panel E, H-bond formation occurs between the carbonyl-oxygen of the
benzoate moiety at the double-ring end of Cpd3-7 and the side chain
hydroxyl hydrogen of S611 and the amide hydrogen of S613. H-bond
formation also occurs the between the hydroxyl oxygen of Cpd3-7 and
the guanidinium hydrogen of R609 and a hydrogen within the
ammonium terminus of K591. In addition, the single ring group of
Cpd3-7 has hydrophobic interactions with the hydrophobic binding site.
In panel F, there are electrostatic interactions between the benzoic acid
group of Cpd30-12 and R609 and K591. H-bond formation occurs
between the carbonyl-oxygen of Cpd30-12 and the guanidinium-
hydrogen of R609, between the carboxyl-oxygen of Cpd30-12 and the
hydroxyl-hydrogen of S611 and between the furyl oxygen of Cpd30-12
andhydrogen withintheammoniumterminusofK591.PanelG showsthe
sequence alignment of residues 585 to 688 of Stat3 and residues 578 to
682 ofStat1eachcontainingtheirrespectiveSH2domains.Residues K591,
R609, S611, E612 and S613 that bind the pY residue are indicated in blue.
Residue E638 that binds to the +3 residue is indicated in green. Residues
W623, Q635, V637, Y640 and Y657 comprising the hydrophobic binding
site are indicated in orange; the region within Stat3 and Stat1 that
contains the hydrophobic binding site is boxed. Residues within LoopbC–
bD and LoopaC–aD of Stat3 are each underlined. Residues identical
between Stat3 and Stat1 are indicated by a dot. Panel H shows an overlay
of tube-and-ribbon models of the SH2 domains of Stat3 (green) and Stat1
(gray). Residues within the hydrophobic binding surface of each are
shown as stick models and LoopbC–bD and LoopaB–aC are indicated. The
van der Waals energy of each compound bound to the Stat1 SH2 domain
or the Stat3 SH2 domain was calculated, normalized to the value for Stat1
and shown in panel I.
doi:10.1371/journal.pone.0004783.g003
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PLoS ONE | www.plosone.org 8 March 2009 | Volume 4 | Issue 3 | e4783pY-peptide ligand interaction would be expected to inhibit nuclear
accumulation of Stat3. To determine if this was the case with our
compounds, we employed a nuclear translocation assay (Figure 4)
using murine embryonic fibroblast (MEF) cells that are deficient in
endogenous Stat3 but constitutively express GFP-tagged Stat3a at
endogenous levels, MEF/GFP-Stat3a [31]. Preincubation of
MEF/GFP-Stat3a cells with Cpd3, Cpd30, Cpd188, Cpd3-2
and Cpd3-7, but not Cpd30-12, blocked ligand-mediated nuclear
translocation of GFP-Stat3a with IC50 values of 131, 77, 39, 150
and 20 mM respectively (Figure 4 and Table 2).
Induction of apoptosis of breast cancer cell lines by
Cpd3, Cpd30 and Cpd188; apoptosis is selective for cell
lines with constitutive Stat3 activation
Previously identified compounds that target Stat3 induce cancer
cell apoptosis [16–18,20,35]. To determine if any of the selective
Stat3 compounds induce apoptosis and whether or not apoptosis
induction is selective for tumor cell lines with constitutive Stat3
activation, we examined each of our Stat3 selective compounds for
the ability to induce apoptosis of breast cancer cell lines, MDA-
MB-231 [36–38], MBA-MB-468 [33,39,40] and MDA-MB-435
[33,39] with constitutively active Stat3 and two breast cancer cell
lines, MDA-MB-453 [17,33,39] and MCF7 [17], without
constitutively active Stat3.
Two compounds—Cpd3 and Cpd30—induced apoptosis of the
three breast cancer cell lines with constitutive Stat3 activity—
MDA-MB-468, MDA-MB-231 and MDA-MB-435 (Figure 5A, B
and C)—with EC50 values ranging from 2.3 to 26.9 mM and from
6.4 to 92.2 mM, respectively (Table 3). In contrast, neither
compound induced apoptosis of cell lines MDA-MB-453 and
MCF7 that do not demonstrate constitutive Stat3 activity in
concentrations up to 300 mM (Figure 5D and E and Table 3).
Cpd188 was even more effective than Cpd3 and Cpd30 at
inducing apoptosis of cell lines with constitutive Stat3 activity
(Figure 5A, B and C and Table 3) demonstrating EC50 values
ranging from 0.7 to 7 mM (mean6SD=3.963.1 mM). Unlike
Cpd3 and Cpd30, however, Cpd188 also had detectable activity
against MDA-MB-453 and MCF7 (Figure 5D and E and Table 3),
demonstrating EC50 values ranging from 17.2 to 15.5 mM,
respectively (mean6SD=16.461.2). Nevertheless, comparison
of the EC50 values of Cpd188 for the two groups of breast cancer
cell lines indicated that, similar to Cpd 3 and Cpd30, Cpd188
showed preferential activity against cell lines with constitutive
Stat3 activity (p=0.014, Student’s t-test). In contrast to Cpd3,
Cpd30 and Cpd188, neither Cpd3-2 nor Cpd3-7 induced
apoptosis of any of the breast cancer cell lines tested (data not
shown).
Discussion
To develop chemical probes that selectively target Stat3, we
virtually screened 920,000 small drug-like compounds by docking
each into the pY-peptide-binding pocket of the Stat3 SH2 domain,
which consisted of three sites—the pY binding site, the +3 residue-
binding site and a hydrophobic binding site. Three compounds
satisfied criteria of interaction analysis, inhibited recombinant
Stat3 binding to its immobilized pY-peptide ligand and inhibited
IL-6-mediated tyrosine phosphorylation of Stat3. These com-
pounds were used in a similarity screen of 2.47 million
compounds, which identified 3 more active compounds. Exami-
nation of the 6 positive compounds for the ability to inhibit IFN-c-
mediated Stat1 phosphorylation revealed that 5 of 6 were selective
for Stat3 vs. Stat1. Sequence and structural analysis of the SH2
domains of Stat3 and Stat1 revealed that the ability of the
compound to interact with the hydrophobic binding site was the
basis for selectivity. All 5 selective compounds inhibited nuclear-to-
cytoplasmic translocation of Stat3, while 3 of 5 preferentially
induced apoptosis of breast cancer cell lines with constitutive Stat3
activation with one compound (Cpd188) active against one breast
cancer cell line (MDA-MB-468) in the sub-micromolar range.
Thus, virtual ligand screening of compound libraries targeting the
pY-peptide binding pocket of the Stat3 SH2 domain identified for
the first time 3 lead compounds that competitively inhibit Stat3
SH2 domain binding to its pY-peptide ligand, selectively target
Stat3 vs. Stat1 and induce apoptosis preferentially of breast cancer
cells lines with constitutively activated Stat3.
Several molecules have been identified recently that target Stat3
[15–20,41–44]. Fluorescence polarization studies indicated that a
peptidomimetic, hydrocinnamoyl-Tyr(PO3H2)-Leu-cis-3,4-
methanoPro-Gln-NHB, was a potent inhibitor of Stat3 binding
to pY-peptide binding with an IC50 of 125 nM [15]. Results of its
ability to inhibit Stat3 phosphorylation or nuclear translocation
within cells have not been reported reflecting, perhaps, the general
obstacle of cell permeability posed by the peptidomimetic class of
drugs.
The G-rich, quartet-forming oligodeoxynucleotide, T40214,
was identified as a Stat3 inhibitor through docking studies of
T40214 onto the known structure of Stat3 [45]. T40214 targeted
Stat3 tail-to-tail homodimers, decreased Stat3 binding to DNA
and inhibited growth of prostate, breast and lung cancer cells in
the nude mouse xenograft model through induction of apoptosis
[20,35,45–47]. T40214 is administered IV or intra-peritoneally in
a complex with polyethyleneimine, which greatly improves
intracellular uptake. To complement these efforts by our group
and to develop a different class of Stat3 inhibitor for use in cancer
treatment with the potential for oral administration, we deter-
mined if recent information obtained regarding the structural
requirements of Stat3 SH2/pY-peptide binding [23,27] could be
exploited to develop a small-molecular inhibitor of Stat3.
Other groups have taken a small-molecule approach to
targeting Stat3 with some success. STA-21 is a small molecule
inhibitor of Stat3 identified through virtual ligand screening of
compounds that bound to the interface of Stat3 SH2 homodimers
[17]. STA-21 treatment of cells disrupted Stat3/DNA complexes,
abrogated Stat3 translocation into the nucleus, inhibited expres-
sion of proteins such as Bcl-XL and Cyclin D1 and induced the
Figure 4. Inhibition of cytoplasmic-to-nuclear translocation of Stat3 assessed by confocal and high-throughput fluorescence
microscopy (HTFM). In panel A, MEF/GFP-Stat3 cells grown on coverslips were pretreated with DMSO that either contained (row four) or did not
contain (row three) Cpd3 (300 mM) for 60 min before being stimulated without (row one) or with IL-6 (200 ng/ml) and IL-6sR (250 ng/ml) for
30 minutes (rows two, three and four). Coverslips were examined by confocal fluorescent microscopy using filters to detect GFP (column one), DAPI
(column two) or both (merge; column three). In panel B, MEF-GFP-Stat3 cells were grown in 96-well plates with optical glass bottoms and pre-treated
with the indicated compound at the indicated concentrations in quadruplicate for 1 hour then stimulated with IL-6 (200 ng/ml) and IL-6sR (250 ng/
ml) for 30 minutes. Cells were fixed and the plates were examined by high-throughput microscopy to determine the fluorescence intensity in the
nucleus (FLIN). The percent of maximum change (delta, D) in FLIN was calculated as described in the Methods and plotted as a function of the log of
the compound concentration. Data shown are mean6SD and are representative of 2 or more experiments. Best-fit curves were determined using 4-
Parameter Logistic Model/Dose Response/XLfit 4.2, IDBS software and were used to calculate the IC50 values (Table 2).
doi:10.1371/journal.pone.0004783.g004
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PLoS ONE | www.plosone.org 9 March 2009 | Volume 4 | Issue 3 | e4783Figure 5. Apoptosis induction of breast cancer cell lines by compounds; selective apoptosis of cell lines that are Stat3 dependent.
MDA-MB-468 (panel A), MDA-MB-231 (panel B), MDA-MB-435 (panel C), MCF7 (panel D) and MDA-MB-453 (panel E) were seeded in 12-well plates,
grown overnight then treated with the indicated compound for 24 hr. Cells were centrifuged and the supernatants assayed for nucleosome levels by
ELISA. The percent maximum nucleosome level was calculated (nucleosome level 4 maximum nucleosome level achieved in the assay 6100) and
plotted as a function of the log compound concentration. The best-fitting curve was determined using 4-ParameterLogistic Model/Dose Response
One Site/XLfit 4.2, IDBS software and was used to determine the EC50 value (Table 3).
doi:10.1371/journal.pone.0004783.g005
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STA-21 bound directly to Stat3 reflecting, perhaps, the non-
availability of suitable reagents i.e. purified Stat3 homodimers.
More recently, a model of STA-21 interaction with the Stat3 SH2
pY-peptide binding pocket has been proposed, which featured the
1-oxygen of STA-21 binding to the side chain ammonium
hydrogen of R609 within the pY-residue binding site. Chemical
modification of STA-21 was undertaken with the goal to generate
compounds with improved interaction at this site. Four com-
pounds were synthesized and the most potent of these demon-
strated activity similar to STA-21 with an EC50 for apoptosis
induction of three Stat3-dependent prostate cancer cell lines with
constitutive Stat3 activity ranging from 13.4 to 34.1 mM [19].
Schust et al. [16] identified another small molecule inhibitor of
Stat3, Stattic, using a fluorescence polarization high throughput
assay of Stat3 binding. This group screened 17,298 chemical
compounds and identified 144 compounds with significant activity
in this assay. The most active compound, Stattic, inhibited Stat3
binding to a cognate pY-peptide ligand, inhibited ligand-mediated
Stat3 phosphorylation and nuclear translocation, reduced Stat3
binding to DNA and induced apoptosis of breast cancer cells with
constitutively activated Stat3 in the 5–20 mM range. Similar to the
compounds we identified, inhibition of ligand-induced phosphor-
ylation was selective for Stat3 vs. Stat1. Unlike our compounds,
however, inhibition of Stat3 by Stattic was blocked by addition of a
reducing agent (dithiothreitol, DTT), was not reversible, and may
not be mediated by direct inhibition of pY-peptide binding.
Rather, Stattic may alter the shape of the Stat3 SH2/pY-peptide
binding site through alkylating the C687 residue on the opposite
side of the SH2 domain [48].
Siddiquee et al. [18] recently identified a small molecule Stat3
inhibitor, S3I-201, using an approach similar to ours that targeted
the Stat3 SH2 pY-peptide binding site. S3I-201 inhibited Stat3
homodimerization, DNA binding, induction of cyclin D1, Bcl-xL
and survivin and induced apoptosis of v-Src-transformed NIH3T3
cells and breast cancer cell lines with constitutively active Stat3 in
the 30 to 100 mM range. Similar to T40214, S3I-201 (5 mg/kg
every 2–3 days) inhibited growth of nude mice xenografts of one of
these breast cancer cell lines (MDA-MB-231). Similar to STA-21,
but unlike the compounds we identified, no evidence of the ability
of S3I-201 to directly bind Stat3 or to inhibit the binding of Stat3
to its pY-peptide ligand was presented leaving open the question of
the precise mechanism of action of S3I-201.
The use of molecular modeling to delineate the structural basis
for competitive inhibition of Stat3 SH2/pY-peptide binding by
our compounds identified the hydrophobic binding site as a
selectivity filter. Molecular modeling also provides a rational basis
for modification of our three lead compounds to identify related
ones with greater potency; these studies are underway. In addition,
the strategy employed here can be used to develop selective
chemical probes for other members of the Stat protein family. In
addition to Stat3 and Stat1, structural information currently is
available for Stat5A [49]. Overlay of the SH2 domains of Stat5A
and Stat1 and of Stat5A and Stat3 revealed differences within the
pY-peptide binding site of Stat5A and both Stat1 and Stat3. We
are currently pursuing VLS screening to exploit these differences
to develop selective chemical probes of Stat5 for use in chemical
genomic studies and as potential therapy for cancers in which
Stat5 contributes to oncogenesis.
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